Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report) – Equities research analysts at HC Wainwright cut their Q4 2026 earnings per share estimates for shares of Brainsway in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.13 for the quarter, down from their prior forecast of $0.16. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.30 per share.
Other equities analysts have also recently issued research reports about the company. Weiss Ratings raised Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday, April 24th. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Zacks Research cut Brainsway from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Brainsway presently has an average rating of “Moderate Buy” and an average target price of $16.00.
Brainsway Trading Down 2.1%
BWAY stock opened at $15.56 on Thursday. Brainsway has a 12-month low of $5.01 and a 12-month high of $17.35. The stock has a market cap of $623.02 million, a price-to-earnings ratio of 44.46 and a beta of 1.23. The business’s 50-day moving average is $14.90 and its 200 day moving average is $12.06.
Brainsway (NASDAQ:BWAY – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million.
Hedge Funds Weigh In On Brainsway
A number of hedge funds have recently made changes to their positions in BWAY. NewEdge Advisors LLC raised its holdings in shares of Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after acquiring an additional 7,549 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Brainsway during the 2nd quarter worth approximately $85,000. Essex Investment Management Co. LLC boosted its holdings in shares of Brainsway by 3.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock worth $4,682,000 after purchasing an additional 9,744 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of Brainsway during the 3rd quarter worth approximately $263,000. Finally, UBS Group AG boosted its holdings in shares of Brainsway by 2,028.6% during the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after purchasing an additional 60,877 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.
Brainsway Company Profile
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Featured Articles
- Five stocks we like better than Brainsway
- Dick’s Sporting Goods Isn’t Done Winning Yet
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
